Patients will be eligible for inclusion in this study if they are newly prescribed dapagliflozin and meet all inclusion criteria and no exclusion criteria.For each dapagliflozin user up to four controls will be matched. Patients with a history of diabetic nephropathy will be included, and this history will be accounted for in the analysis.